Patients with psoriasis have a higher level of interleukin-30 (IL-30) than healthy patients, according to a recent study. A new study has found that patients with psoriasis have a higher level of ...

Called sonelokimab, the product inhibits both the A and F isoforms of interleukin-17 (IL-17). In this mid-stage trial, well ...

Icotrokinra demonstrated superiority to placebo and deucravacitinib in the treatment of adults and adolescents with moderate ...

Anti-IL-17A biologics have the greatest odds of achieving and maintaining clear or almost clear skin among patients with psoriasis.

The interleukin-23 inhibitors market is witnessing robust growth driven by the rising prevalence of autoimmune diseases like psoriasis and inflammatory bowel disease. Advancements in biologics and ...

Psoriasis is a chronic inflammatory autoimmune disease that manifests as red, scaly skin patches. There is no causal treatment for the disease, but the symptoms can be significantly alleviated with ...

The interleukin-17 isoforms -- interleukin-17A and interleukin-17F -- are implicated in the pathophysiology of psoriasis and there is evidence that dual inhibition also blocks interleukin-17F/F. This ...

Interleukin-12 - a messenger molecule of immune cells - was long considered to trigger the development of psoriasis. Now, researchers at the University of Zurich have shown that interleukin-12 does ...

The experimental monoclonal antibody brodalumab, an interleukin 17 (IL-17) receptor antagonist, achieved a 100% reduction in plaque psoriasis symptoms in twice as many patients as the commonly used ...

Interleukin-12 -- a messenger molecule of immune cells -- was long considered to trigger the development of psoriasis. Now, researchers have shown that interleukin-12 does not actually cause the skin ...